These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
154 related items for PubMed ID: 34519297
21. Platinum(IV)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light. Shaili E, Romero MJ, Salassa L, Woods JA, Butler JS, Romero-Canelón I, Clarkson G, Habtemariam A, Sadler PJ, Farrer NJ. Dalton Trans; 2021 Aug 04; 50(30):10593-10607. PubMed ID: 34278398 [Abstract] [Full Text] [Related]
22. Strategy for Traceless Codrug Delivery with Platinum(IV) Prodrug Complexes Using Self-Immolative Linkers. Lee VEY, Lim ZC, Chew SL, Ang WH. Inorg Chem; 2021 Feb 01; 60(3):1823-1831. PubMed ID: 33464875 [Abstract] [Full Text] [Related]
23. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells. Chen CK, Zhang JZ, Aitken JB, Hambley TW. J Med Chem; 2013 Nov 14; 56(21):8757-64. PubMed ID: 24107138 [Abstract] [Full Text] [Related]
24. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions. Navas F, Chocarro-Calvo A, Iglesias-Hernández P, Fernández-García P, Morales V, García-Martínez JM, Sanz R, De la Vieja A, García-Jiménez C, García-Muñoz RA. J Med Chem; 2024 Apr 25; 67(8):6410-6424. PubMed ID: 38592014 [Abstract] [Full Text] [Related]
25. What do we know about the reduction of Pt(IV) pro-drugs? Wexselblatt E, Gibson D. J Inorg Biochem; 2012 Dec 25; 117():220-9. PubMed ID: 22877926 [Abstract] [Full Text] [Related]
26. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D. J Med Chem; 2021 Aug 12; 64(15):11364-11378. PubMed ID: 34342437 [Abstract] [Full Text] [Related]
27. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance. Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H. Bioorg Chem; 2019 Nov 12; 92():103236. PubMed ID: 31494328 [Abstract] [Full Text] [Related]
28. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo. Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY. Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239 [Abstract] [Full Text] [Related]
29. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon. Yue Z, Wang H, Li Y, Qin Y, Xu L, Bowers DJ, Gangoda M, Li X, Yang HB, Zheng YR. Chem Commun (Camb); 2018 Jan 18; 54(7):731-734. PubMed ID: 29303526 [Abstract] [Full Text] [Related]
30. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug. Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G. Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087 [Abstract] [Full Text] [Related]
31. A New Approach to Sensitize Antitumor Monofunctional Platinum(II) Complexes via Short Time Photo-Irradiation. Xue X, Zhu C, Chen H, Bai Y, Shi X, Jiao Y, Chen Z, Miao Y, He W, Guo Z. Inorg Chem; 2017 Apr 03; 56(7):3754-3762. PubMed ID: 28080031 [Abstract] [Full Text] [Related]
32. Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes. Lorenzo J, Delgado A, Montaña ÁM, Mesas JM, Alegre MT, Rodríguez Mdel C, Avilés FX. Eur J Med Chem; 2014 Aug 18; 83():374-88. PubMed ID: 24980119 [Abstract] [Full Text] [Related]
33. Glucose-Appended Platinum(II)-BODIPY Conjugates for Targeted Photodynamic Therapy in Red Light. Ramu V, Gautam S, Garai A, Kondaiah P, Chakravarty AR. Inorg Chem; 2018 Feb 19; 57(4):1717-1726. PubMed ID: 29400953 [Abstract] [Full Text] [Related]
34. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design. Zhang JZ, Bonnitcha P, Wexselblatt E, Klein AV, Najajreh Y, Gibson D, Hambley TW. Chemistry; 2013 Jan 28; 19(5):1672-6. PubMed ID: 23255183 [Abstract] [Full Text] [Related]
35. Curcumin "Drug" Stabilized in Oxidovanadium(IV)-BODIPY Conjugates for Mitochondria-Targeted Photocytotoxicity. Bhattacharyya U, Kumar B, Garai A, Bhattacharyya A, Kumar A, Banerjee S, Kondaiah P, Chakravarty AR. Inorg Chem; 2017 Oct 16; 56(20):12457-12468. PubMed ID: 28972748 [Abstract] [Full Text] [Related]
36. Expanding the Arsenal of PtIV Anticancer Agents: Multi-action PtIV Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Yempala T, Babu T, Karmakar S, Nemirovski A, Ishan M, Gandin V, Gibson D. Angew Chem Int Ed Engl; 2019 Dec 09; 58(50):18218-18223. PubMed ID: 31599054 [Abstract] [Full Text] [Related]
37. Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups. Zhou Q, Chen S, Xu Z, Liu G, Zhang S, Wang Z, Tse MK, Yiu SM, Zhu G. Angew Chem Int Ed Engl; 2023 Apr 24; 62(18):e202302156. PubMed ID: 36878864 [Abstract] [Full Text] [Related]
38. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands. Deng Z, Zhu G. Curr Opin Chem Biol; 2023 Jun 24; 74():102303. PubMed ID: 37075513 [Abstract] [Full Text] [Related]
39. Electrodrugs: an electrochemical prodrug activation strategy. Norman DJ, González-Fernández E, Clavadetscher J, Tucker L, Staderini M, Mount AR, Murray AF, Bradley M. Chem Commun (Camb); 2018 Aug 14; 54(66):9242-9245. PubMed ID: 30066701 [Abstract] [Full Text] [Related]
40. Oxoplatin-B, a cisplatin-based platinum(IV) complex with photoactive BODIPY for mitochondria specific "chemo-PDT" activity. Bera A, Gautam S, Raza MK, Kondaiah P, Chakravarty AR. J Inorg Biochem; 2021 Oct 14; 223():111526. PubMed ID: 34246120 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]